Aggregometry and thromboelastography to identify the timing to trach a COVID-19 patient receiving both antiplatelet therapy and enoxaparin.
Marco TescioneEugenio VadalàGraziella MaranoAndrea BruniEugenio GarofaloOvidia LavalleFederico LonghiniEnzo BattagliaNicola PolimeniDemetrio LabateSarah CaraccioloFrancesco GiordanoMassimo CaraccioloSebastiano MachedaPublished in: Clinical case reports (2021)
In COVID-19 patients receiving enoxaparin and antiplatelets therapy, aggregometry and thromboelastography might be considered an adjunctive tool to identify the time to perform procedures at risk of bleeding, such as tracheostomy.
Keyphrases
- antiplatelet therapy
- coronavirus disease
- sars cov
- venous thromboembolism
- acute coronary syndrome
- percutaneous coronary intervention
- atrial fibrillation
- case report
- respiratory syndrome coronavirus
- coronary artery disease
- mechanical ventilation
- mesenchymal stem cells
- intensive care unit
- stem cells
- extracorporeal membrane oxygenation
- smoking cessation
- replacement therapy